A randomized, placebo-controlled trial of 13-valent pneumococcal conjugate vaccination to accelerate immune recovery after sepsis | Science Translational Medicine
The VACIRiSS trial in adult sepsis survivors shows that PCV13 at ICU discharge did not perform better than placebo, with variable immunogenicity.
